Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an announcement.
Newron Pharmaceuticals reported that shareholders at its 2026 General Meeting approved all items on the ordinary agenda, including the election of George Garibaldi and Paolo Zocchi as new independent, non-executive board members, while the extraordinary agenda was not voted on due to a lack of quorum. The board transition, which also sees the departure of long-serving members Patrick Langlois and Luca Benatti, signals continuity in governance as the company advances its late-stage CNS pipeline, notably Evenamide for treatment-resistant schizophrenia, with potential implications for its strategic direction and oversight at a pivotal development phase.
The most recent analyst rating on (CH:NWRN) stock is a Buy with a CHF48.00 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals is a biopharmaceutical company based in Bresso near Milan, Italy, specializing in novel therapies for disorders of the central and peripheral nervous system. Its lead candidate Evenamide, a first-in-class glutamate modulator for treatment-resistant schizophrenia, is in a global phase III program, while its marketed drug Xadago for Parkinson’s disease is sold across major regions through partners including Zambon, Supernus and Meiji Seika.
Average Trading Volume: 102,504
Technical Sentiment Signal: Buy
Current Market Cap: CHF341.2M
See more insights into NWRN stock on TipRanks’ Stock Analysis page.